Pfizer Inc. (NYSE:PFE) recently used the 23andMe gene database to identify 15 genome sites linked with depression. 23andME is currently reporting an increased demand to access its personal genetics pioneer's repository.
Considering Pfizer Inc.'s (NYSE:PFE) deal worth $14 billion in order to acquire Medivation Inc (NASDAQ:MDVN), analyst Do Kim at BMO Capital believes the deal has increased the attractiveness of the other mid-cap companies in the bio-tech segment.
Pfizer Inc. currently has a total float of 6.07 billion shares and moves 19.2 million a day, on average. The stock opened at $34.80 on August 22 and traded between a low of $34.76 and a high of $35.28.